Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent

Research output: Contribution to journalArticlepeer-review

150 Scopus citations


Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including mesothelioma, breast, colorectal, bladder, cervical, gastric and pancreatic cancer. In non-small cell lung cancer, single-agent activity has been documented in the first- and second-line settings in Phase II and Phase III trials. Promising activity has also been demonstrated when pemetrexed is combined with platinum compounds (cisplatin, carboplatin, and oxaliplatin), vinorelbine, and gemcitabine. Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect.

Original languageEnglish (US)
Pages (from-to)4276s-4280s
JournalClinical Cancer Research
Issue number12 II
StatePublished - Jul 15 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent'. Together they form a unique fingerprint.

Cite this